Magnetic Resonance for Differential Diagnosis of Left Ventricular Hypertrophy: Diagnostic and Prognostic Implications.
echocardiography
left ventricular hypertrophy
magnetic resonance
prognosis
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
27 Jan 2022
27 Jan 2022
Historique:
received:
03
01
2022
revised:
19
01
2022
accepted:
26
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
Left ventricular hypertrophy (LVH) may be due to different causes, ranging from benign secondary forms to severe cardiomyopathies. Transthoracic Echocardiography (TTE) and ECG are the first-level examinations for LVH diagnosis. Cardiac magnetic resonance (CMR) accurately defines LVH type, extent and severity. to evaluate the diagnostic and prognostic role of CMR in patients with TTE and/or ECG evidence of LVH. We performed CMR in 300 consecutive patients with echocardiographic and/or ECG signs of LVH. Overall, 275 patients had TTE evidence of LVH, with initial suspicion of hypertrophic cardiomyopathy (HCM) in 132 (44%), cardiac amyloidosis in 41 (14%), hypertensive LVH in 48 (16%), aortic stenosis in 4 (1%), and undetermined LVH in 50 (16%). The initial echocardiographic diagnostic suspicion of LVH was confirmed in 172 patients (57.3%) and changed in 128 patients (42.7%, CMR changed echocardiographic suspicion in almost half of patients with LVH. In the subgroup of patients with abnormal ECG, CMR identified LVH (particularly HCM) in 80% of patients. This study highlights the indication of CMR to better characterize the type, extent and severity of LVH detected at echocardiography and suspected with ECG.
Sections du résumé
BACKGROUND
BACKGROUND
Left ventricular hypertrophy (LVH) may be due to different causes, ranging from benign secondary forms to severe cardiomyopathies. Transthoracic Echocardiography (TTE) and ECG are the first-level examinations for LVH diagnosis. Cardiac magnetic resonance (CMR) accurately defines LVH type, extent and severity.
OBJECTIVES
OBJECTIVE
to evaluate the diagnostic and prognostic role of CMR in patients with TTE and/or ECG evidence of LVH.
METHODS
METHODS
We performed CMR in 300 consecutive patients with echocardiographic and/or ECG signs of LVH.
RESULTS
RESULTS
Overall, 275 patients had TTE evidence of LVH, with initial suspicion of hypertrophic cardiomyopathy (HCM) in 132 (44%), cardiac amyloidosis in 41 (14%), hypertensive LVH in 48 (16%), aortic stenosis in 4 (1%), and undetermined LVH in 50 (16%). The initial echocardiographic diagnostic suspicion of LVH was confirmed in 172 patients (57.3%) and changed in 128 patients (42.7%,
CONCLUSIONS
CONCLUSIONS
CMR changed echocardiographic suspicion in almost half of patients with LVH. In the subgroup of patients with abnormal ECG, CMR identified LVH (particularly HCM) in 80% of patients. This study highlights the indication of CMR to better characterize the type, extent and severity of LVH detected at echocardiography and suspected with ECG.
Identifiants
pubmed: 35160102
pii: jcm11030651
doi: 10.3390/jcm11030651
pmc: PMC8836982
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
JACC Cardiovasc Imaging. 2016 Dec;9(12):1392-1402
pubmed: 27450876
JACC Cardiovasc Imaging. 2020 May;13(5):1221-1234
pubmed: 31542534
N Engl J Med. 1990 May 31;322(22):1561-6
pubmed: 2139921
Eur Heart J. 2005 Aug;26(15):1461-74
pubmed: 15831557
Prog Cardiovasc Dis. 2012 Mar-Apr;54(5):387-96
pubmed: 22386289
Am J Cardiol. 2017 Feb 15;119(4):643-650
pubmed: 27956002
Curr Heart Fail Rep. 2020 Oct;17(5):192-204
pubmed: 32844347
Heart. 2004 Jun;90(6):645-9
pubmed: 15145868
Br J Radiol. 1999 Mar;72(855):258-64
pubmed: 10396215
Circulation. 2014 Aug 5;130(6):484-95
pubmed: 25092278
Am J Hypertens. 1995 Mar;8(3):221-8
pubmed: 7794570
Circ Cardiovasc Imaging. 2017 Aug;10(8):
pubmed: 28794137
Eur Heart J. 2014 Oct 14;35(39):2733-79
pubmed: 25173338
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Am Heart J. 1949 Feb;37(2):161-86
pubmed: 18107386
J Cardiovasc Magn Reson. 2010 Apr 07;12:21
pubmed: 20374627
J Magn Reson Imaging. 2017 Apr;45(4):1055-1067
pubmed: 27571232
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
Heart Fail Rev. 2015 Mar;20(2):133-44
pubmed: 25549885
JACC Cardiovasc Imaging. 2010 Feb;3(2):155-64
pubmed: 20159642
J Am Heart Assoc. 2019 Apr 16;8(8):e012250
pubmed: 30957681
J Cardiovasc Magn Reson. 2020 Feb 24;22(1):17
pubmed: 32089132
Circulation. 2005 Aug 9;112(6):855-61
pubmed: 16087809
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
Eur Heart J. 2014 Aug 7;35(30):2010-20
pubmed: 24126876
Hypertens Res. 1999 Mar;22(1):1-9
pubmed: 10221344
Am Heart J. 2001 Mar;141(3):334-41
pubmed: 11231428
J Am Coll Cardiol. 2012 Sep 4;60(10):922-9
pubmed: 22935464